title: [Limited but potential efficacy by graft-versus-leukemia (GVL) for Pro T-ALL].
abstract: We present a 22-year-old male diagnosed with pro T-acute lymphoblastic leukemia (ALL). His laboratory test showed 181,900/microL of WBC complicated with lymphoadenopathy, pleural effusion, pericardial effusion and hepatosplenomegaly at the onset. Flow cytometry analysis of the leukemic cells showed cCD3+, CD7+, CD2+, CD1a-, CD3-, CD5-, CD4-, CD8-, CD34+, and HLA-DR+ as a pro T-cell phenotype. The patient was treated with induction therapy followed by 3 courses of consolidation therapy and achieved his first complete remission. He underwent up-front stem cell transplantation (SCT) from an HLA-full matched sibling, with early relapse just before transplantation. The conditioning regimen consisted of fludarabine (100 mg/m2) and melphalan (180 mg/m2). He relapsed with an extramedullary mass (gingival, testis, and femoral muscles) 1 year after transplantation. Since bone marrow involvement was not apparent, he received involved field radiation therapy (25.2 Gy/14 frequencies) in each mass. Six months after extramedullary relapse, bone marrow relapse occurred, and the patient died of sepsis due to Pseudomonas aeruginosa during re-induction therapies. Based on the immature T cell phenotype frequently with myeloid markers, a graft-versus- leukemic effect might be expected after allogeneic SCT for Pro T-ALL and a positive indication of SCT for this disease should be considered.
authors.affiliation: Division of Hematology, Dept. of Internal Medicine, Kagawa University.
authors.forename: Osamu
authors.initials: O
authors.lastname: Imataki
authors.forename: Airi
authors.initials: A
authors.lastname: Koike
authors.forename: Masako
authors.initials: M
authors.lastname: Iwabu
authors.forename: Takamichi
authors.initials: T
authors.lastname: Shintani
authors.forename: Fusako
authors.initials: F
authors.lastname: Waki
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Ohue
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ohnishi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishida
mesh_terms: D003131:Combined Modality Therapy; D020544:Graft vs Leukemia Effect / Q000276:immunology*; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology* / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D017211:Treatment Failure; D055815:Young Adult